Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$210.25+1.1%$194.55$163.81▼$218.66$371.42B0.56.57 million shs2.52 million shsMRKMerck & Co., Inc.$84.13+1.1%$82.04$73.31▼$120.30$210.14B0.3815.26 million shs6.44 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.16%-0.78%+8.69%+12.06%+6.34%MRKMerck & Co., Inc.-1.10%-3.28%+0.57%+8.29%-29.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.7009 of 5 stars2.54.03.33.93.32.51.3MRKMerck & Co., Inc.4.9963 of 5 stars3.25.05.04.23.11.73.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.96Moderate Buy$214.952.24% UpsideMRKMerck & Co., Inc. 2.35Hold$107.4427.70% UpsideCurrent Analyst Ratings BreakdownLatest MRK and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/12/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$231.008/11/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/7/2025ABBVAbbVieDaiwa AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/7/2025ABBVAbbVieDaiwa Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$214.008/1/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$250.00 ➝ $255.008/1/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$216.00 ➝ $227.008/1/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$227.00 ➝ $236.007/30/2025MRKMerck & Co., Inc.Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$97.00 ➝ $90.007/10/2025MRKMerck & Co., Inc.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $98.006/11/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$205.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.59$15.09 per share13.93($0.08) per share-2,628.14MRKMerck & Co., Inc.$64.17B3.27$9.47 per share8.88$19.64 per share4.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10100.1215.041.346.45%699.66%13.64%10/29/2025 (Estimated)MRKMerck & Co., Inc.$17.12B$6.4912.968.500.8925.79%41.05%16.55%10/30/2025 (Estimated)Latest MRK and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.12%N/A312.38%53 YearsMRKMerck & Co., Inc.$3.243.85%N/A49.92%14 YearsLatest MRK and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/22/2025MRKMerck & Co., Inc.quarterly$0.813.97%9/15/20259/15/202510/7/20256/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61MRKMerck & Co., Inc.0.691.421.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%MRKMerck & Co., Inc.0.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableMRKMerck & Co., Inc.75,0002.50 billion2.49 billionOptionableMRK and ABBV HeadlinesRecent News About These CompaniesABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?5 hours ago | zacks.comWealth Preservation Advisors LLC Takes Position in Merck & Co., Inc. $MRKAugust 29 at 8:24 AM | marketbeat.comB. Metzler seel. Sohn & Co. AG Raises Holdings in Merck & Co., Inc. $MRKAugust 29 at 8:10 AM | marketbeat.comGuggenheim Capital LLC Raises Stock Position in Merck & Co., Inc. $MRKAugust 29 at 7:36 AM | marketbeat.comIeq Capital LLC Purchases 13,155 Shares of Merck & Co., Inc. $MRKAugust 29 at 7:14 AM | marketbeat.comRafferty Asset Management LLC Sells 52,722 Shares of Merck & Co., Inc. $MRKAugust 29 at 6:15 AM | marketbeat.comEpoch Investment Partners Inc. Has $63.54 Million Position in Merck & Co., Inc. $MRKAugust 29 at 6:14 AM | marketbeat.comMerck: Buy the Next Dip Despite Short-Term PressuresAugust 28 at 1:17 PM | fxempire.comFMerck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?August 28 at 12:36 PM | zacks.comMRK, Daiichi Begin Phase III Breast Cancer Study With ADC CandidateAugust 28 at 12:16 PM | zacks.comWill Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?August 28 at 10:26 AM | zacks.comZuckerman Investment Group LLC Has $6.71 Million Holdings in Merck & Co., Inc. $MRKAugust 28 at 9:30 AM | marketbeat.comQuadcap Wealth Management LLC Sells 4,262 Shares of Merck & Co., Inc. $MRKAugust 28 at 9:13 AM | marketbeat.comGABELLI & Co INVESTMENT ADVISERS INC. Purchases New Shares in Merck & Co., Inc. $MRKAugust 28 at 9:12 AM | marketbeat.comRedwood Investment Management LLC Purchases 22,138 Shares of Merck & Co., Inc. $MRKAugust 28 at 9:11 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Sold by Gabelli Funds LLCAugust 28 at 8:37 AM | marketbeat.comFORA Capital LLC Raises Stock Holdings in Merck & Co., Inc. $MRKAugust 28 at 7:54 AM | marketbeat.comCauseway Capital Management LLC Has $80.59 Million Holdings in Merck & Co., Inc. $MRKAugust 28 at 7:43 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Purchased by Harvest Portfolios Group Inc.August 28 at 7:26 AM | marketbeat.comMerck to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 28 at 7:02 AM | businesswire.comMerck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC AdvancesAugust 28 at 6:31 AM | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025AbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025MRK and ABBV Company DescriptionsAbbVie NYSE:ABBV$210.25 +2.33 (+1.12%) Closing price 03:59 PM EasternExtended Trading$210.55 +0.30 (+0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Merck & Co., Inc. NYSE:MRK$84.13 +0.92 (+1.11%) Closing price 03:59 PM EasternExtended Trading$84.12 -0.01 (-0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big Chevron Stock Outlook: Dividend Growth Meets Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access